Latest News of MRNS
Great week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous year
By Yahoo! Finance |
1 month ago
Understanding a stock's ownership structure and analyst forecasts can reveal investment opportunities. Marinus Pharmaceuticals, Inc. is primarily institution-owned, with hedge funds owning 23%. Top sh...
Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?
By Yahoo! Finance |
3 months ago
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a biopharmaceutical company focused on treating rare epilepsies. Despite challenges, its potential lies in the growth of its primary asset, ganaxolone. A...